
Arthroplasty
Continuous FNB superior to single-shot FNB for pain reduction after total knee arthroplasty
Adv Ther. 2020 Feb;37(2):671-685.Seven studies including 525 patients were included in this meta-analysis comparing continuous or single-shot femoral nerve blockade (FNB) for the relief of pain following total knee arthroplasty (TKA). The primary outcomes of interest were pooled pain scores and morphine consumption. Secondary outcomes of interest included pooled Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index, length of stay and the incidence of post-operative nausea and vomiting. Results revealed significantly favourable pooled pain scores at rest and during physical therapy at post-operative day 1 and overall in the continuous FNB group compared to the single-shot FNB group. No significant differences in pooled pain scores at post-operative day 2 were observed between groups. Pooled morphine consumption was significantly lower in the continuous FNB group compared to the single-shot FNB group at post-operative days 1 and 2, as well as overall. No significant differences in the pooled WOMAC score, length of stay or post-operative nausea or vomiting were observed between the two groups.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.